Study #2023-0214
A prospective feasibility study using cTDNA to tailor neoadjuvant chemotherapy for patients with Colorectal or Appendiceal Adenocarcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Description
To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help doctors decide if less or more intense chemotherapy is needed as treatment before surgery. ctDNA testing measures the amount of tumor DNA (genetic information) in the blood.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Appendiceal Adenocarcinoma;Colorectal
Study phase:
Not applicable
Physician name:
Michael White
Department:
Colon and Rectal Surgery
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.